4-氯-6-(1H-吡唑-1-基)嘧啶 | 114833-95-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-6-(1H-吡唑-1-基)嘧啶
• 英文名称: 4-chloro-6-(1H-pyrazol-1-yl)pyrimidine
• 英文别名: 4-chloro-6-pyrazol-1-ylpyrimidine
• CAS: 114833-95-3
• 化学式: C₇H₅ClN₄
• mdl: MFCD00297274
• 分子量: 180.596
• InChiKey: HDRFFLHBLUPAKE-UHFFFAOYSA-N

物化性质

• 熔点：
  128-129 °C(Solv: hexane (110-54-3))
• 沸点：
  324.0±27.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine
CAS number: 114833-95-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5ClN4
Molecular weight: 180.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-6-(1H-吡唑-1-基)嘧啶 在 palladium on activated charcoal 氢气 、 sodium acetate 作用下， 以 甲醇 为溶剂， 以96%的产率得到(9CI)-4-(1H-吡唑-1-基)-嘧啶
  参考文献：
  名称：

  Synthesis and Cytoprotective Antiulcer Activity of 2- or 4-(lH-Pyrazol-1-yl)pyrimidine Derivatives Related to Mepirizole and Dulcerozine.

  摘要：

  (1H-吡唑-1-基)、(1H-咪唑-1-基)和(1H-1, 2, 4-三唑-1-基)嘧啶的衍生物被合成并评估其细胞保护的抗溃疡活性。其中，4-甲氧基-6-甲基-2-(1H-吡唑-1-基)嘧啶（18）显示出对盐酸-乙醇诱导和水浸应激诱导的溃疡具有强效的抑制作用，并且急性毒性低。

  DOI：

  10.1248/cpb.44.1700
• 作为产物：
  描述：

  吡唑 、 4,6-二氯嘧啶 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以66%的产率得到4-氯-6-(1H-吡唑-1-基)嘧啶
  参考文献：
  名称：

  [EN] A MOLECULAR GLUE REGULATING CDK12-DDB1 INTERACTION TO TRIGGER CYCLIN K DEGRADATION
  [FR] COLLE MOLÉCULAIRE RÉGULANT L'INTERACTION CDK12-DDB1 POUR DÉCLENCHER UNE DÉGRADATION DE LA CYCLINE K

  摘要：

  提供了一种新型的分子胶，用于触发CCNK（cyclin K）的多泛素化和降解。具体来说，这是一种新型的分子胶，用于创建修饰的CDK12蛋白，以便结合DDB1-CUL4-RBX1的DDB1。这种分子胶将CDK12转化为特定底物受体，从而触发CCNK的多泛素化和随后的降解。

  公开号：

  WO2021249517A1

文献信息

• [EN] QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] COMPOSÉ DE QUINUCLIDINE COMME LIGANDS DU RÉCEPTEUR NICOTINIQUE ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011053292A1

  公开（公告）日：2011-05-05

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱7受体的配体，可能对治疗中枢神经系统的各种紊乱，特别是情感和神经退行性疾病有用。
• [EN] SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 6- (1H-PYRAZOL-1-YL) PYRIMIDIN-4-AMINE SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：BAYER AG

  公开号：WO2018069222A1

  公开（公告）日：2018-04-19

  The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）所述和定义的取代6-(1H-吡唑-1-基)嘧啶-4-胺化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一活性成分或与其他活性成分组合使用，用于治疗和/或预防心血管和肾脏疾病。
• Pyrimidine derivatives
  申请人：Nissin Shokuhin Kabushiki Kaisha

  公开号：US04849424A1

  公开（公告）日：1989-07-18

  The present invention relates to novel pyrimidine derivatives of the general formula ##STR1## wherein R.sup.1 represents a pyrazolyl, imidazolyl, or triazolyl group, R.sup.2 represents hydrogen atom or lower alkyl group, R.sup.3 represents a halo, amino, lower alkoxy, pyrazolyl, imidazolyl, triazolyl, piperidinyl, or aryloxy group, one of X or Y represents N and the other of X or Y represents CH, and the salts thereof. These derivatives may be used in the treatment of peptic ulcer disease.

  本发明涉及一种通式为##STR1##的新型嘧啶衍生物，其中R.sup.1代表吡唑基、咪唑基或三唑基，R.sup.2代表氢原子或较低的烷基基团，R.sup.3代表卤素、氨基、较低的烷氧基、吡唑基、咪唑基、三唑基、哌啶基或芳基氧基，X或Y中的一个代表N，另一个代表CH，以及其盐。这些衍生物可用于治疗消化性溃疡病。
• AMINO ACID COMPOUNDS AND METHODS OF USE
  申请人：Pliant Therapeutics, Inc.

  公开号：US20190276449A1

  公开（公告）日：2019-09-12

  The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R 1 , R 2 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  该发明涉及以下化合物的公式(A)和公式(I)：或其盐，其中R1、R2、R10、R11、R12、R13、R14、R15、R16、q和p如本文所述。公式(A)、公式(I)的化合物及其药物组合物是αvβ6整合素抑制剂，可用于治疗纤维化疾病，如特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• [EN] DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS<br/>[FR] FORMES POSOLOGIQUES ET SCHÉMAS DE TRAITEMENT POUR DES COMPOSÉS D'ACIDES AMINÉS
  申请人：PLIANT THERAPEUTICS INC

  公开号：WO2020210404A1

  公开（公告）日：2020-10-15

  The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ανβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP),

  该发明涉及用于每日给药的化合物(A)和化合物(I)的剂型：或其盐，其中R1、R2、R10、R11、R12、R13、R14、R15、R16、q和p如本文所述。化合物(A)、化合物(I)及其药物组成物是ανβ6整合素抑制剂，可用于治疗纤维化疾病，如特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。